Biology:Nexvax2
Nexvax2® is a potential vaccine for celiac disease being developed by ImmusanT.[1]Nexvax2® is the only disease-modifying therapeutic approach for celiac disease in clinical development today.[2]
Nexvax2 is a therapeutic vaccine that combines three proprietary peptides that elicit an immune response in patients with celiac disease who carry the immune recognition gene HLA-DQ2. In an approach similar to treatments for allergies to dander from cats and dust mites, Nexvax2 is designed to reprogram gluten-specific T cells triggered by the patient’s immune response to the protein. The goal is for Nexvax2 to restore celiac patients’ immune tolerance to gluten, reduce inflammation in the nutrient-absorbing villi that line the small intestine, return the intestine to a healthy state, and allow patients to eat a normal diet.
Status
Nexvax2® has completed Phase 1-b human trials. Results of this clinical trial support a dosing regimen for a planned Phase 2 clinical trial of Nexvax2 in patients with celiac disease.
In September, 27, the 2nd phase starts. [3]
References
- ↑ "Nexvax2 << ImmusanT". http://www.immusant.com/nexvax2/.
- ↑ "ImmusantFactSheet". http://www.immusant.com/clinical-development/celiac-disease-programs.php.
- ↑ "Immusant Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease". http://www.immusant.com/docs/ImmusanT%201004%20Study%20Completion%20FINAL%2002.22.17.pdf.
 |
